Cetuximab: all 645 studies that test it

Page 1 of 7. Open to participants first (75), then studies with results posted, then the rest; newest registration first within each.

• A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingNCT07814417Phase 2
• Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07733466Phase 2
• Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingNCT07724223Phase 2
• A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingNCT07678593Phase 1/2
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingNCT07659795Phase 2
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerRecruitingNCT07644559Phase 2
• BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitationNCT07618624Phase 2
• SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RCRecruitingNCT07549399Phase 3
• A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal CancerNot yet recruitingNCT07543471Phase 1
• A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D MutationRecruitingNCT07535112Phase 1
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2
• Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal CancerNot yet recruitingNCT07490119Phase 2
• Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive CisplatinRecruitingNCT07441681Phase 3
• Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07432087Phase 3
• Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")RecruitingNCT07411599Phase 1/2
• Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal CancerRecruitingNCT07389265Phase 3
• ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingNCT07381764Phase 2
• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)RecruitingNCT07209111Phase 2
• The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal CancerRecruitingNCT07204574Phase 1/2
• Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot yet recruitingNCT07094893Phase 4
• Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07079410Phase 2
• A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 2
• Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerNot yet recruitingNCT07059949Phase 2
• ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRCRecruitingNCT07012954Phase 1/2
• A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingNCT06997497Phase 3
• FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver MetastasisRecruitingNCT06988852Phase 2
• Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
• Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.RecruitingNCT06869473Phase 2
• FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingNCT06865664Phase 1
• Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal CancerRecruitingNCT06776757Phase 1/2
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06728618Phase 2
• Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)Not yet recruitingNCT06647563Phase 3
• Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&NRecruitingNCT06640725Phase 2
• Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingNCT06640166Phase 2
• Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal CancerRecruitingNCT06603376Phase 2
• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 3
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer StudyRecruitingNCT06547203Phase 2
• Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or CetuximabRecruitingNCT06540326Phase 2
• Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative GenesNot yet recruitingNCT06490913Phase 2
• Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell CarcinomaRecruitingNCT06448026Phase 2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNARecruitingNCT06440902Phase 2
• Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT06418724Phase 2
• A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsRecruitingNCT06412198Phase 1/2
• Combination Therapy for BRAF-V600E Metastatic CRCmRecruitingNCT06411600Phase 2
• Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRCRecruitingNCT06379399Phase 1/2
• Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingNCT06369259Phase 2
• ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingNCT06321081Phase 2
• Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal CancerRecruitingNCT06279351Phase 2
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingNCT06239220Phase 2
• Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerRecruitingNCT06231017Phase 2
• Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal CancerRecruitingNCT06226857Phase 3
• Crisaborole Ointment for Skin Toxicity Induced by CetuximabRecruitingNCT06118047Phase 2
• Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06107114Phase 2
• Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingNCT06102902Phase 1
• Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1
• Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant TherapyNot yet recruitingNCT06035133Not applicable
• Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapyRecruitingNCT05962502Phase 2
• Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeRecruitingNCT05956821Phase 1/2
• Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLMNot yet recruitingNCT05948072Phase 3
• A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell CancersRecruitingNCT05910827Phase 1/2
• Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal AdenocarcinomasRecruitingNCT05745857Phase 2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC DetectionNot yet recruitingNCT05720559Phase 2
• Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerRecruitingNCT05706779Phase 2
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1
• FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver MetastasesRecruitingNCT04832776Phase 2
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell CancerRecruitingNCT04375384Phase 2
• Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer PatientsRecruitingNCT03874026Phase 2
• Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal CancerRecruitingNCT03391934Phase 3
• Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck DistrictRecruitingNCT03001570Phase 2
• Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignRecruitingNCT02128906Phase 2
• A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedNCT06024174Phase 1/2Results posted
• A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal CancerTerminatedNCT05619172Phase 2Results posted
• Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminatedNCT05167409Phase 2Results posted
• Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal CancerTerminatedNCT04853043Phase 2Results posted
• Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsTerminatedNCT04717375Phase 1/2Results posted
• Study of NKTR 255 in Combination With Cetuximab in Solid TumorsCompletedNCT04616196Phase 1/2Results posted
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT04607421Phase 3Results posted
• MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent CetuximabCompletedNCT04554836Phase 2Results posted
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)CompletedNCT04495621Phase 1/2Results posted
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results posted
• Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerActive, not recruitingNCT04117945Phase 2Results posted
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell CancerActive, not recruitingNCT03944941Phase 2Results posted
• Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º ChemotherapyTerminatedNCT03887442Phase 2Results posted
• Cetuximab in Head and Neck Cancer PatientsCompletedNCT03769311Phase 2Results posted
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLCCompletedNCT03717155Phase 2Results posted
• Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedNCT03693170Phase 2Results posted
• Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03691714Phase 2Results posted
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedNCT03646461Phase 2Results posted
• Palbociclib and Cetuximab in Metastatic Colorectal CancerCompletedNCT03446157Phase 2Results posted
• Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaCompletedNCT03422536Phase 2Results posted
• QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedNCT03387111Phase 1/2Results posted
• Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03370276Phase 1/2Results posted
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT03365882Phase 2Results posted
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerCompletedNCT03349710Phase 3Results posted

← Cetuximab overview